Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
Author:
- 9 August 2018
- journal article
- review article
- Published by Springer Nature in Targeted Oncology
- Vol. 13 (4) , 525-532
Abstract
The intravenous CD22-directed antibody drug conjugate inotuzumab ozogamicin (Besponsa®) is approved in several countries including in the USA, EU and Japan, as monotherapy for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukaemia (ALL). In adults with relapsed/refractory B-cell ALL who had received one or two prior treatment regimens, inotuzumab ozogamicin was associated with significantly higher rates of complete remission (including complete remission with incomplete haematological recovery) [CR/CRi] than standard therapy in the pivotal INO-VATE ALL trial. Inotuzumab ozogamicin was associated with significantly longer progression-free survival (PFS), duration of remission and higher haematopoietic stem cell transplantation (HSCT) rates than standard therapy. Although there was no significant between-group difference in overall survival duration as per the study design, the 2-year survival probability in the inotuzumab ozogamicin arm was twice that in the control arm. Inotuzumab ozogamicin had an acceptable tolerability profile. Thus, inotuzumab ozogamicin is an important new treatment option for patients with relapsed/refractory CD22-positive B-cell ALL.Keywords
This publication has 20 references indexed in Scilit:
- Inotuzumab Ozogamicin: First Global ApprovalDrugs, 2017
- Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 studyBlood Advances, 2017
- Inotuzumab ozogamicin in relapsed B‐cell acute lymphoblastic leukemiaEuropean Journal of Haematology, 2017
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2016
- The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemiaTherapeutic Advances in Hematology, 2015
- Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab OzogamicinClinical Lymphoma Myeloma and Leukemia, 2013
- Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaBlood, 2013
- The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cellsLeukemia, 2011
- Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemiaLeukemia, 2007
- Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignanciesBlood, 2004